Last updated: August 13, 2026
Definium Therapeutics’ DT120, an orally disintegrating tablet of lysergide, reduced Hamilton Anxiety Rating Scale scores by 11.6 points versus 6.2 for placebo at Week 12 in the Phase 3 Voyage study, a 5.4 point placebo adjusted difference (p<0.0001) from a single 100 µg dose.
This page covers the full Voyage dataset and what comes next for DT120, plus the day’s other developments: safety questions around Neurocrine’s Vykat XR, Aardvark’s terminated Prader-Willi trials, Boulevard Bio’s $65 million launch, and K2 Therapeutics’ $50 million seed round.
What did Definium’s DT120 show in the Phase 3 Voyage trial?
Voyage met its primary endpoint. A single 100 µg dose of DT120 produced an 11.6 point drop on the HAM-A anxiety scale at Week 12 versus 6.2 for placebo, a 5.4 point placebo adjusted difference with p<0.0001 and an effect size of 0.81.
The trial randomized 214 adults aged 18 to 74 with generalized anxiety disorder across roughly 35 US sites in a double blind, placebo controlled design. DT120 (lysergide orally disintegrating tablet) is pharmaceutical grade LSD in a controlled, single administration format. Improvement was evident by Day 2 and held through the 12 week measurement window, which is the striking part: one dose, three months of effect.
| Voyage Phase 3 measure | DT120 100 µg | Placebo |
|---|---|---|
| HAM-A change at Week 12 (LS mean) | −11.6 | −6.2 |
| Placebo adjusted difference | −5.4 points, p<0.0001, effect size d=0.81 | |
| HAM-A response (≥50% improvement) | 43% | 16% |
| HAM-A remission (score ≤7) | 14% | 4% |
| CGI-Severity change at Week 12 | −1.0 | −0.4 |
| Onset of improvement | Evident by Day 2 | |
All figures are from the company’s August 12 topline announcement.
How big is a 5.4 point difference in an anxiety trial?
Large by the standards of the field. Jefferies analyst Andrew Tsai noted the separation exceeded the roughly five point bar Wall Street had set, and an effect size of 0.81 sits well above what registrational trials of daily anxiety medications typically show against placebo.
The HAM-A runs to 56 points, and approved daily medications for generalized anxiety disorder have historically cleared regulatory review with placebo adjusted differences in the low single digits. Stifel’s Paul Matteis called the readout “a clean win” with “continued robust durability.” The response rate gap, 43 percent versus 16 percent, and the remission gap, 14 percent versus 4 percent, both moved in the same direction as the primary endpoint, which matters because single endpoint wins with soft secondaries are a recurring pattern in failed CNS franchises.
How safe was a single 100 µg dose of DT120?
Treatment emergent adverse events were mild to moderate, transient, and concentrated on dosing day, with no new safety signals and no signal of suicidal ideation. Per BioPharma Dive’s coverage, 92 percent of participants met the end of session discharge checklist within the eight hour monitoring window.
That monitoring window is the operational heart of this product. Dosing happens in a supervised setting, and the discharge statistic is the number that tells clinics how to schedule a treatment room. The tolerability profile, with adverse events largely confined to the day of administration, is the trade this class offers: an intense, contained treatment day in exchange for months without a daily pill.
What happens next for DT120, and when could it reach patients?
The near term catalyst is Panorama, the second Phase 3 study in generalized anxiety disorder, with topline results expected in September 2026. Definium has not given a filing date. Full major depression program data are expected in 2027, and a late stage PTSD program is planned.
Voyage is Definium’s second Phase 3 win in as many months, following the Emerge study in major depressive disorder in June. Two things sit between strong data and a launch. First, the regulatory package: a second positive GAD study would give the company the conventional two study foundation for a filing. Second, scheduling: lysergide is a Schedule I controlled substance, so alongside any FDA approval the DEA would need to complete a scheduling action before the product could be marketed, and a monitored administration model, similar in spirit to the REMS programs used for other in clinic treatments, is the widely expected shape of any label. Chief executive Rob Barrow said the results “should raise the bar for what patients and clinicians expect from GAD treatments.”
What do analysts think DT120 could be worth?
Peak sales estimates published this week cluster around $2 billion for anxiety alone, with similar figures for depression. These are analyst models, not company guidance, and they carry the usual caveats about pricing, access, and the delivery bottleneck discussed above.
| Source | Estimate | Scope |
|---|---|---|
| Evercore ISI (Gavin Clark-Gartner) | ~$2B peak annual sales | Generalized anxiety disorder |
| Evercore ISI (Gavin Clark-Gartner) | ~$2B / ~$1B | Depression / PTSD |
| Leerink Partners (Marc Goodman, June 2026) | $1.5B to $2B | Major depression alone |
Definium shares (Nasdaq: DFTX) rose about 15 percent at Wednesday’s open to just over $47 before settling near $43 by mid morning, per BioPharma Dive.
Why is Prader-Willi syndrome suddenly a market with two broken options?
Because the only approved drug for the syndrome’s hallmark hunger is under a post marketing safety cloud, and the leading challenger formally scrapped its Phase 3 trials the same day. Both developments landed on August 12, and together they leave the community with hard choices.
On the approved side, STAT reported that a group of Prader-Willi clinicians has flagged roughly seven deaths and about 100 serious adverse event reports in the FDA’s adverse event reporting system for Neurocrine Biosciences’ Vykat XR (diazoxide choline), approved in March 2025 as the first treatment for hyperphagia in the syndrome. Reported complications include swelling, respiratory problems, and cardiac events, and the Prader-Willi Syndrome Association issued a caution to families on Tuesday. Adverse event reports do not establish that the drug caused any of these outcomes, a point both the company and careful readers of FAERS data should insist on. Neurocrine said the drug “has a compelling risk-benefit profile in the context of a very serious disease” and that it is working with the FDA on post marketing surveillance. Shares opened about 2 percent lower Wednesday.
On the pipeline side, Aardvark Therapeutics confirmed in its second quarter report that it has terminated the Phase 3 HERO trial and its open label extension for ARD-101, along with the related ARD-201 obesity work, after the FDA placed a full clinical hold on the program in May following reversible cardiac observations in healthy volunteers. The company, which cut staff in June, reported $73.9 million in cash at June 30, guides its runway into late 2027, and plans to assess the unblinded Phase 3 data this quarter before deciding a path forward. Per Fierce Biotech, Aardvark does not currently intend to resume the trials as previously designed.
| Date | Prader-Willi event |
|---|---|
| March 2025 | FDA approves Vykat XR, first drug for PWS hyperphagia |
| February 2026 | Aardvark voluntarily pauses Phase 3 HERO after cardiac observations |
| May 2026 | FDA places full clinical hold on ARD-101 program |
| June 2026 | Aardvark terminates HERO and OLE trials, cuts workforce |
| August 11, 2026 | PWSA issues safety caution to families on Vykat XR |
| August 12, 2026 | STAT reports clinician concerns; Aardvark confirms terminations in Q2 report |
What is Boulevard Bio, and why does its launch matter for IgA nephropathy?
Boulevard Bio launched August 12 with $65 million from Deerfield Management and affiliates to build precision immunology drugs aimed at durable disease control, with a lead bispecific antibody against BAFF and APRIL already in Phase 1 for IgA nephropathy.
The company was cofounded by Prof. Georg Schett, the rheumatologist whose work on immune reset helped define the current wave of autoimmune cell therapy, with Frank Nestle of Deerfield as scientific cofounder, Mahesh Karande as chief executive, and Neil Solomons, a nephrology drug veteran, as chief medical officer. It is headquartered in New York at Cure, Deerfield’s innovation campus.
| Program | Modality and target | Indication | Stage |
|---|---|---|---|
| BLVD101 | Bispecific antibody, BAFF and APRIL | IgA nephropathy | Phase 1; data support a 12 week dosing interval |
| BLVD201 | Trispecific T cell engager, CD19/BCMA/CD3 | Severe B cell driven autoimmune disease | IND enabling |
| BLVD301 | Undisclosed target combination | B cell driven autoimmune disease | Candidate nominated June 2026 |
The IgA nephropathy field Boulevard is entering already has three leaders we track: Vera Therapeutics’ Trutakna (atacicept), which is approved; Novartis’ Fabhalta (iptacopan), which holds full approval and works through complement; and Vertex’s povetacicept, a dual BAFF and APRIL antagonist with a November 30 FDA action date. Two of those three attack the same BAFF and APRIL axis as BLVD101, so Boulevard’s differentiation case rests on antibody format and a quarterly dosing pitch against more frequent regimens.
What is K2 Therapeutics planning with $50 million?
K2 Therapeutics named former Legend Biotech chief executive Ying Huang as CEO alongside a $50 million seed financing backed by MPM BioImpact. The model is asset hunting: in licensing drug candidates from around the world, including China, into a purpose built company.
Endpoints News reported the company is already eyeing a Series A of roughly $250 million. Huang ran Legend through the development and launch of Carvykti, one of the defining products of the China originated wave, which makes him a credible buyer in exactly the cross border market where US licensing of Chinese assets exceeded $137 billion last year. The open question for every vehicle built on that trade is political: deals signed are safe, but the Biotech Investment National Security Act, still awaiting a committee vote, would route future China deals through Treasury review.
Frequently asked questions
What is DT120, and how is it taken?
DT120 is pharmaceutical grade lysergide (LSD) formulated as an orally disintegrating tablet. In the Phase 3 Voyage study it was given as a single supervised 100 µg dose, with participants monitored in clinic for eight hours on dosing day.
Did the Voyage trial meet its primary endpoint?
Yes. DT120 reduced HAM-A anxiety scores by 11.6 points at Week 12 versus 6.2 for placebo, a 5.4 point placebo adjusted difference with p<0.0001 and an effect size of 0.81.
How fast did DT120 start working?
Improvement in anxiety symptoms was evident by Day 2 after the single dose, per the company’s topline announcement, and the benefit persisted through the Week 12 primary measurement.
How long does one dose of DT120 last?
Voyage measured benefit out to 12 weeks after a single dose, and the effect held across that window. Durability beyond 12 weeks, and the question of retreatment intervals, will be defined by longer follow up and the second Phase 3 study.
Was DT120 safe in the Voyage study?
Adverse events were mild to moderate, transient, and mostly limited to dosing day, with no new safety signals and no signal of suicidal ideation. Per BioPharma Dive, 92 percent of participants met discharge criteria within the eight hour monitoring window.
Is DT120 the same thing as LSD?
The active molecule is lysergide, which is LSD, but DT120 is a standardized pharmaceutical formulation given at a controlled 100 µg dose under clinical supervision. That is a different exposure, setting, and safety context from unregulated use.
Has DT120 worked in any other condition?
Yes. In June 2026 the Emerge Phase 3 study of DT120 in major depressive disorder read out positively, making Voyage the company’s second successful Phase 3 in two months. Full depression program data are expected in 2027.
When will Definium file DT120 for FDA approval?
The company has not given a filing date. The second Phase 3 anxiety study, Panorama, reads out in September 2026, and a conventional filing package would build on two positive controlled studies plus long term safety data.
Would DT120 need DEA action before launch?
Yes. Lysergide is a Schedule I controlled substance, so in addition to FDA approval, the DEA would need to complete a scheduling action covering the approved product before it could be marketed and prescribed.
What happened with Neurocrine’s Vykat XR this week?
STAT reported that Prader-Willi clinicians flagged roughly seven deaths and about 100 serious adverse event reports in FDA safety data for Vykat XR, and the Prader-Willi Syndrome Association issued a caution to families. Neurocrine defended the drug’s risk benefit profile.
Do the Vykat XR reports prove the drug caused the deaths?
No. FAERS style adverse event reports document what happened to patients taking a drug, not what the drug caused, and reporting is uneven. They are a signal for investigation, which is what clinicians are asking the FDA and the company to pursue.
Why did Aardvark scrap its Phase 3 Prader-Willi trials?
The FDA placed a full clinical hold on ARD-101 in May 2026 after reversible cardiac observations in healthy volunteers. Aardvark terminated the HERO trial and its extension in June, and says it does not intend to resume them as designed. It will assess unblinded data this quarter.
What is Boulevard Bio’s lead drug?
BLVD101, a bispecific antibody blocking both BAFF and APRIL, is in Phase 1 for IgA nephropathy with data supporting a 12 week dosing interval. Boulevard launched August 12 with $65 million from Deerfield Management and affiliates.
How does BLVD101 compare with Vertex’s povetacicept?
Both block BAFF and APRIL, the B cell survival signals implicated in IgA nephropathy. Povetacicept is a fusion protein with a November 30, 2026 FDA action date; BLVD101 is an earlier stage antibody whose pitch is quarterly dosing.
Who is behind K2 Therapeutics?
Former Legend Biotech CEO Ying Huang now leads K2, which announced a $50 million seed financing backed by MPM BioImpact. The company plans to in license drug candidates globally, including from China, and Endpoints reports it is eyeing a roughly $250 million Series A.
Sources
Primary sources
- Definium Therapeutics, topline Phase 3 Voyage results announcement (Business Wire), August 12, 2026
- Aardvark Therapeutics, second quarter 2026 financial results and business update (investor relations), August 11, 2026
- Boulevard Bio launch announcement (PR Newswire), August 12, 2026
- K2 Therapeutics, CEO appointment and $50 million seed financing announcement (GlobeNewswire), August 11, 2026
- Neurocrine Biosciences company statement on Vykat XR, as quoted in coverage below, August 12, 2026
Reporting and analysis
- STAT, reporting on Vykat XR adverse event reports and clinician concerns, August 12, 2026
- BioPharma Dive, Definium Phase 3 coverage with analyst commentary, August 12, 2026
- BioSpace, Vykat XR safety coverage and Definium readout coverage, August 12, 2026
- Fierce Biotech, Aardvark trial termination coverage, August 12, 2026
- Endpoints News, K2 Therapeutics Series A reporting, August 12, 2026
